Physician profile
Eva Geracimos
NPI 1750344784
$703.78
in general payments reported to CMS, 2019-2025
14 companies · $26.82 in 2025
The $26.82 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $426 · 2020: $74.45 · 2021: $21.02 · 2022: $23.20 · 2023: $29.68 · 2024: $103 · 2025: $26.82.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $159.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $159.03 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $180.20 | 2021-2025 | |
| Pfizer INC. | $74.18 | 2019 | |
| Amgen INC. | $70.73 | 2019-2020 | |
| Shire North American Group INC | $65.19 | 2019 | |
| Lilly USA, LLC | $63.52 | 2019-2020 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $55.80 | 2019-2020 | |
| Sunovion Pharmaceuticals INC. | $40.39 | 2019 | |
| Astellas Pharma US INC | $37.56 | 2019 | |
| Merck Sharp & Dohme LLC | $26.29 | 2019-2020 | |
| Allergan, INC. | $23.08 | 2019 | |
| Sumitomo Pharma America, INC. | $23.05 | 2024 | Gemtesa |
| Novo Nordisk INC | $17.43 | 2019 | |
| Adlon Therapeutics L.P. | $15.18 | 2020 | |
| Circassia INC. | $11.18 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Eva Geracimos listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.